Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for AmericansBusiness Wire • 12/19/25
Exclusive: US FDA taps Merck drugs with blockbuster sales potential for national priority vouchersReuters • 12/17/25
Pfizer, Merck Are Boring Again — And That's Exactly Why 2026 Investors Are Circling BackBenzinga • 12/17/25
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After SurgeryBusiness Wire • 12/17/25
Should You Buy the 5 Highest-Paying Dividend Stocks in the Dow Jones Before 2026?The Motley Fool • 12/16/25
MRK Gets Positive CHMP Opinion for Expanded Use of Winrevair in PAHZacks Investment Research • 12/15/25
Should You Forget Teva Pharmaceutical and Buy These Unstoppable Stocks Instead?The Motley Fool • 12/14/25
Can MRK's New Drugs & Pipeline Help Navigate the Looming Keytruda LOE?Zacks Investment Research • 12/12/25
Merck Receives Positive EU CHMP Opinion for Expanded Use of WINREVAIR™ (sotatercept) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)Business Wire • 12/12/25
MRK Stock Trading Above 200- & 50-Day SMA for 2 Months: Time to Buy?Zacks Investment Research • 12/09/25